Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by retiredcopon May 16, 2018 3:38pm
93 Views
Post# 28041465

RE:RE:RE:Pathetic Performance

RE:RE:RE:Pathetic PerformanceOh yes .. good old George... How much of the 3 deals wth Biogen was actually hard cash and how much was share options they bought as a type of financing. We had to put up with Biogen disposing of all the shares they got for the next 2-3 years after the stock started to drop in 2009.

Were you by chance at the meeting in 2009 at the Moose Factory, just after the shares pluimetted on the negative news that Amorfix was stepping away from its vcjd project involving the UK Blood Service, which a few months prior was what took the shares to record highs. A sure thing that was sabotoged and caused the boys in Califronia wine country,  to unload over 2.5 million in shares in 2 days and cause a massive sell off like we never saw before.

Did you hear him repeatedly stress at that meeting , that Amorfix had signed an agreement with a company to develop a blood test fo liver cancer ... it was a sure thing and it would briung us back into the promised land and the vcjd was something we could forget about.  I will never forgive him for deceiving us and keeping such a straight face. This the same George Adams that while doing the tour for Amorifx was also tyring to convince Amortifx shereholders to invest in the new Medical company that was developing some type of heart valve or similar...he was a board member and I think he eventually became CEO after leaving Amorfix. 

Yep... he was a pretty incredible leader...      
Bullboard Posts